Innate Pharma S.A.
IPHA
$1.36
-$0.06-4.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 649.60K | 652.40K | 948.20K | 879.20K | 2.31M |
| Total Other Revenue | 1.76M | 1.77M | 1.81M | 1.68M | 1.84M |
| Total Revenue | 2.41M | 2.42M | 2.76M | 2.56M | 4.14M |
| Cost of Revenue | 13.45M | 13.50M | 11.64M | 10.80M | 12.21M |
| Gross Profit | -11.03M | -11.08M | -8.89M | -8.24M | -8.06M |
| SG&A Expenses | 5.60M | 5.63M | 5.54M | 5.14M | 5.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.05M | 19.13M | 17.19M | 15.94M | 17.61M |
| Operating Income | -16.64M | -16.71M | -14.43M | -13.38M | -13.46M |
| Income Before Tax | -16.20M | -16.27M | -12.11M | -11.23M | -13.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.20M | -16.27M | -12.11M | -11.23M | -13.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.20M | -16.27M | -12.11M | -11.23M | -13.17M |
| EBIT | -16.64M | -16.71M | -14.43M | -13.38M | -13.46M |
| EBITDA | -16.04M | -16.11M | -14.22M | -13.19M | -12.80M |
| EPS Basic | -0.18 | -0.18 | -0.14 | -0.13 | -0.16 |
| Normalized Basic EPS | -0.11 | -0.11 | -0.09 | -0.08 | -0.10 |
| EPS Diluted | -0.18 | -0.18 | -0.14 | -0.13 | -0.16 |
| Normalized Diluted EPS | -0.11 | -0.11 | -0.09 | -0.08 | -0.10 |
| Average Basic Shares Outstanding | 92.25M | 92.25M | 86.94M | 86.94M | 81.23M |
| Average Diluted Shares Outstanding | 92.25M | 92.25M | 86.94M | 86.94M | 81.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |